Shelley Wood

The Indian-made valve, available in nine sizes, still needs to deliver on outcomes in a randomized trial, experts agreed.

The dedicated device can lacerate bioprosthetic leaflets poised to cause coronary obstruction—and does it quickly.

Interventional news dominated this month, but a few stories on heart failure and cardiometabolic disease also made the list.

Remembered as incisive, driven, curious, and kind, Connolly died Saturday of neuroendocrine cancer.

We Recommend Predicted PPM picked up fewer “severe” cases than did measured PPM, providing some validation for VARC-3 recommendations.

A study tracking CV risks with a low-cal sweetener topped a diverse list of stories spanning meeting updates and sex advice.

This long-awaited RCT, seen by some as a COAPT/MITRA-FR tiebreaker, will be unveiled at ESC 2024—with key design tweaks.

A packed program leaves little time for warm beer or Buckingham Palace as the London edition of CVD's biggest congress kicks off.

A flurry of papers, including a meta-analysis of the three RCTs, reflect big interest and even larger, unanswered questions.

Critics were quick to point out that this small, short-term trial—mostly in patients with preserved EF—had no medical arm.